European Cancer Stem Cell Research Institute and Cardiff School of Biosciences, Cardiff University, Hadyn Ellis Building, Maindy Road, Cardiff CF24 4HQ, UK.
Almac Diagnostic Services, Craigavon BT63 5QD,UK.
Dis Model Mech. 2021 May 1;14(5). doi: 10.1242/dmm.048736. Epub 2021 May 18.
Understanding the mechanisms underlying tumour heterogeneity is key to the development of treatments that can target specific tumour subtypes. We have previously targeted CRE recombinase-dependent conditional deletion of the tumour suppressor genes Brca1, Brca2, p53 (also known as Trp53) and/or Pten to basal or luminal oestrogen receptor-negative (ER-) cells of the mouse mammary epithelium. We demonstrated that both the cell-of-origin and the tumour-initiating genetic lesions cooperate to influence mammary tumour phenotype. Here, we use a CRE-activated HER2 orthologue to specifically target HER2/ERBB2 oncogenic activity to basal or luminal ER- mammary epithelial cells and perform a detailed analysis of the tumours that develop. We find that, in contrast to our previous studies, basal epithelial cells are less sensitive to transformation by the activated NeuKI allele, with mammary epithelial tumour formation largely confined to luminal ER- cells. Histologically, most tumours that developed were classified as either adenocarcinomas of no special type or as metaplastic adenosquamous tumours. The former were typically characterized by amplification of the NeuNT/Erbb2 locus; in contrast, tumours displaying squamous metaplasia were enriched in animals that had been through at least one pregnancy and typically had lower levels of NeuNT/Erbb2 locus amplification but had activated canonical WNT signalling. Squamous changes in these tumours were associated with activation of the epidermal differentiation cluster. Thus, in this model of HER2 breast cancer, cell-of-origin, reproductive history, NeuNT/Erbb2 locus amplification and the activation of specific branches of the WNT signalling pathway all interact to drive inter-tumour heterogeneity.
了解肿瘤异质性的机制是开发针对特定肿瘤亚型的治疗方法的关键。我们之前曾针对 CRE 重组酶依赖性条件性缺失肿瘤抑制基因 Brca1、Brca2、p53(也称为 Trp53)和/或 Pten,以靶向小鼠乳腺上皮的基底或腔雌激素受体阴性(ER-)细胞。我们证明了细胞起源和起始肿瘤遗传损伤都合作影响乳腺肿瘤表型。在这里,我们使用 CRE 激活的 HER2 同源物特异性靶向 HER2/ERBB2 致癌活性到基底或腔 ER-乳腺上皮细胞,并对发展中的肿瘤进行详细分析。我们发现,与我们之前的研究相反,基底上皮细胞对激活的 NeuKI 等位基因的转化敏感性较低,乳腺上皮肿瘤形成主要局限于腔 ER-细胞。组织学上,大多数发展中的肿瘤被归类为非特殊类型的腺癌或化生腺鳞瘤。前者通常表现为 NeuNT/Erbb2 基因座的扩增;相比之下,显示鳞状化生的肿瘤在经历至少一次妊娠的动物中更为丰富,通常具有较低水平的 NeuNT/Erbb2 基因座扩增,但具有激活的经典 WNT 信号通路。这些肿瘤中的鳞状变化与表皮分化簇的激活有关。因此,在这种 HER2 乳腺癌模型中,细胞起源、生殖史、NeuNT/Erbb2 基因座扩增以及 WNT 信号通路特定分支的激活都相互作用,导致肿瘤间异质性。